Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer

Research output: Contribution to journal › Comment/debate › peer-review

ASJC Scopus subject areas

@article{803079c63e7f4f86bbac9675a3709a39,

title = "Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer",

author = "C. Bertelsen and D. Tripathy",

year = "2012",

doi = "10.1016/j.breastdis.2012.06.030",

language = "English (US)",

volume = "23",

pages = "284--285",

journal = "Breast Diseases",

issn = "1043-321X",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer

AU - Bertelsen, C.

AU - Tripathy, D.

PY - 2012

Y1 - 2012

UR - http://www.scopus.com/inward/record.url?scp=84865688682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865688682&partnerID=8YFLogxK

U2 - 10.1016/j.breastdis.2012.06.030

DO - 10.1016/j.breastdis.2012.06.030

M3 - Comment/debate

AN - SCOPUS:84865688682

SN - 1043-321X

VL - 23

SP - 284

EP - 285

JO - Breast Diseases

JF - Breast Diseases

IS - 3

ER -